Semaglutide treatment for children with obesity: an observational study.

van Boxel EJ, Rahman S, Lai K, Boulos N, Davis N

Archives of disease in childhood25 Sept 2024Cited by 18 (Europe PMC)

PMID38471743DOI10.1136/archdischild-2023-326687PepBankPUB-38471743

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In children aged 10-18 with obesity, BMI SDS fell significantly after 6 months of semaglutide.
In plain wordsIn children with obesity, BMI score fell after 6 months of semaglutide, with diet and lifestyle advice.
Peptide
Semaglutide
Outcome
DecreaseBMI SDS change at 6 months
Study
n = 50
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 6 monthsAs given in this study (human).
Measurements
BMI SDS decrease
0.32 SDS
6 months
Source sentences
Summary
After 6 months of treatment, statistically significant decreases in BMI SDS (0.32±0.27, p<0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174301
02HumanObservational studyEfficacy outcome
In children aged 10-18 with obesity, body weight fell significantly after 6 months of semaglutide.
In plain wordsIn children with obesity, body weight fell after 6 months of semaglutide, with diet and lifestyle advice.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 6 months
Study
n = 50
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 6 monthsAs given in this study (human).
Measurements
Body weight decrease
7.03 kg
6 months
Source sentences
Summary
After 6 months of treatment, statistically significant decreases in BMI SDS (0.32±0.27, p<0.001) and body weight (7.03±7.50 kg, p<0.001) were seen.
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174302
03HumanObservational studyEfficacy outcome
In children aged 10-18 with obesity, mean percentage total weight loss was 6.4% after 6 months of semaglutide.
In plain wordsIn children with obesity, average weight loss was 6.4% after 6 months of semaglutide with diet and lifestyle advice.
Peptide
Semaglutide
Outcome
DecreasePercentage total weight loss at 6 months
Study
n = 50
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 6 monthsAs given in this study (human).
Measurements
Percentage total weight loss
6.4%
6 months
Source sentences
Summary
Mean percentage total weight loss was 6.4±6.3% (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174303
04HumanObservational studyEfficacy outcome
In 14 children with 12-month data, BMI SDS fell significantly after 12 months of semaglutide.
In plain wordsIn 14 children with obesity who had 12-month data, BMI score fell over 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBMI SDS change at 12 months
Study
n = 14
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 12 monthsAs given in this study (human).
Measurements
BMI SDS decrease
0.54 SDS
12 months
Source sentences
Summary
For the 14 patients for whom 12-month data were available, statistically significant decreases were seen in mean BMI SDS (0.54±0.52, p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174304
05HumanObservational studyEfficacy outcome
In 14 children with 12-month data, mean body weight fell by 9.7 kg over 12 months of semaglutide.
In plain wordsIn 14 children with obesity who had 12-month data, body weight fell by 9.7 kg on average.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 12 months
Study
n = 14
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 12 monthsAs given in this study (human).
Measurements
Body weight decrease
9.7 kg
12 months
Source sentences
Summary
Mean body weight decreased by 9.7±10.8 kg (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174305
06HumanObservational studyEfficacy outcome
In 14 children with 12-month data, percentage total weight loss was 8.9% at 12 months of semaglutide.
In plain wordsIn 14 children with obesity who had 12-month data, average weight loss was 8.9% at 12 months.
Peptide
Semaglutide
Outcome
DecreasePercentage total weight loss at 12 months
Study
n = 14
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · 12 monthsAs given in this study (human).
Measurements
Percentage total weight loss
8.9%
12 months
Source sentences
Summary
Percentage total weight loss at 12 months was 8.9±10.0% (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcome measures were change in weight, BMI SDS and percentage body weight.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174306
07HumanObservational studySafety outcome
In children aged 10-18 with obesity, mild gastrointestinal side effects were common with semaglutide.
In plain wordsIn children with obesity, mild stomach and gut side effects were common with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal side effects
Study
n = 50
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · at least 6 monthsAs given in this study (human).
Source sentences
Summary
Mild gastrointestinal side effects were common.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were side effects and cessation of treatment.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174307
08HumanObservational studySafety outcome
In children aged 10-18 with obesity treated with semaglutide, one patient developed gallstones.
In plain wordsIn children with obesity treated with semaglutide, one child developed gallstones.
Peptide
Semaglutide
Outcome
IncreaseGallstones
Study
n = 50
Analysis
Secondary
Outcome group
Adverse events · Gastrointestinal
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · at least 6 monthsAs given in this study (human).
Source sentences
Summary
One patient developed gallstones.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were side effects and cessation of treatment.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174308
09HumanObservational studySafety outcome
In children aged 10-18 with obesity, five patients stopped semaglutide because of side effects.
In plain wordsIn children with obesity, five children stopped semaglutide because of side effects.
Peptide
Semaglutide
Outcome
IncreaseDiscontinuation due to side effects
Study
n = 50
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
titrated over 8 weeks to a final dose of 1 mg · injection · at least 6 monthsAs given in this study (human).
Source sentences
Summary
Five patients discontinued treatment due to side effects.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were side effects and cessation of treatment.
Summary · context
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.
Summary · context
Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).
Report a problemFND-3847174309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.